Literature DB >> 35348360

Practical steps to identifying the research risk of pragmatic trials.

Scott Yh Kim1, Jonathan Kimmelman2.   

Abstract

BACKGROUND: Pragmatic randomized clinical trials that compare two or more purportedly "within the standard of care" interventions attempt to provide real-world evidence for policy and practice decisions. There is considerable debate regarding their research risk status, which in turn could lead to debates about appropriate consent requirements. Yet no practical guidance for identifying the research risks of pragmatic randomized clinical trials is available.
METHODS: We developed a practical, four-step process for identifying and evaluating the research risk of pragmatic trials that can be applied to those pragmatic randomized clinical trials that compare two or more "standard of care" or "accepted" interventions.
RESULTS: Using a variety of examples of standard of care pragmatic randomized clinical trials (ranging from trials comparing: insurance coverage conditions, patient reminders for health screens, intensive care unit procedures, post-stroke interventions, and drugs for life-threatening conditions), we illustrate in a four-step process how any pragmatic randomized clinical trial purportedly comparing standard interventions can be evaluated for their research risks.
CONCLUSION: Although determining the risk status of a standard of care pragmatic randomized clinical trial is only one necessary element in the ethical oversight of such pragmatic randomized clinical trials, it is a central element. Our four-step process of pragmatic randomized clinical trial risk determination provides a practical, transparent, and systematic approach with likely low risk of bias.

Entities:  

Keywords:  Research risk; comparative effectiveness; pragmatic; standard of care

Year:  2022        PMID: 35348360      PMCID: PMC9038618          DOI: 10.1177/17407745211063476

Source DB:  PubMed          Journal:  Clin Trials        ISSN: 1740-7745            Impact factor:   2.599


  27 in total

1.  Is informed consent always necessary for randomized, controlled trials? .

Authors:  R D Truog; W Robinson; A Randolph; A Morris
Journal:  N Engl J Med       Date:  1999-03-11       Impact factor: 91.245

2.  Considerations in the evaluation and determination of minimal risk in pragmatic clinical trials.

Authors:  John D Lantos; David Wendler; Edward Septimus; Sarita Wahba; Rosemary Madigan; Geraldine Bliss
Journal:  Clin Trials       Date:  2015-09-15       Impact factor: 2.486

3.  OHRP and standard-of-care research.

Authors: 
Journal:  N Engl J Med       Date:  2014-11-12       Impact factor: 91.245

4.  Low risk pragmatic trials do not always require participants' informed consent.

Authors:  Rafael Dal-Ré; Cristina Avendaño-Solà; Brigitte Bloechl-Daum; Anthonius de Boer; Stefan Eriksson; Uwe Fuhr; Søren Holm; Stefan K James; Robert J Mentz; Emilio Perucca; Frits R Rosendaal; Shaun Treweek
Journal:  BMJ       Date:  2019-03-27

5.  Ethics and regulatory complexities for pragmatic clinical trials.

Authors:  Jeremy Sugarman; Robert M Califf
Journal:  JAMA       Date:  2014-06-18       Impact factor: 56.272

6.  Misdirections in Informed Consent - Impediments to Health Care Innovation.

Authors:  David A Asch; Tracy A Ziolek; Shivan J Mehta
Journal:  N Engl J Med       Date:  2017-10-12       Impact factor: 91.245

7.  Harms, benefits, and the nature of interventions in pragmatic clinical trials.

Authors:  Joseph Ali; Joseph E Andrews; Carol P Somkin; C Egla Rabinovich
Journal:  Clin Trials       Date:  2015-09-15       Impact factor: 2.486

8.  A framework for analysis of research risks and benefits to participants in standard of care pragmatic clinical trials.

Authors:  Stephanie C Chen; Scott Yh Kim
Journal:  Clin Trials       Date:  2016-06-30       Impact factor: 2.486

9.  Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial.

Authors:  Adeel Shahzad; Ian Kemp; Christine Mars; Keith Wilson; Claire Roome; Rob Cooper; Mohammed Andron; Clare Appleby; Mike Fisher; Aleem Khand; Babu Kunadian; Joseph D Mills; John L Morris; William L Morrison; Shahzad Munir; Nick D Palmer; Raphael A Perry; David R Ramsdale; Periaswamy Velavan; Rod H Stables
Journal:  Lancet       Date:  2014-07-04       Impact factor: 79.321

10.  Target ranges of oxygen saturation in extremely preterm infants.

Authors:  Waldemar A Carlo; Neil N Finer; Michele C Walsh; Wade Rich; Marie G Gantz; Abbot R Laptook; Bradley A Yoder; Roger G Faix; Abhik Das; W Kenneth Poole; Kurt Schibler; Nancy S Newman; Namasivayam Ambalavanan; Ivan D Frantz; Anthony J Piazza; Pablo J Sánchez; Brenda H Morris; Nirupama Laroia; Dale L Phelps; Brenda B Poindexter; C Michael Cotten; Krisa P Van Meurs; Shahnaz Duara; Vivek Narendran; Beena G Sood; T Michael O'Shea; Edward F Bell; Richard A Ehrenkranz; Kristi L Watterberg; Rosemary D Higgins
Journal:  N Engl J Med       Date:  2010-05-16       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.